Nat Commun:EZH2甲基化ERG K362位点并增强前列腺癌中TMPRSS2-ERG的致癌活性

2021-07-14 xiaozeng MedSci原创

ETS转录因子是一类控制细胞增殖、分化和致癌作用的信号依赖性转录调节因子家族。

ETS转录因子是一类控制细胞增殖、分化和致癌作用的信号依赖性转录调节因子家族。既往研究显示,在约一半的前列腺肿瘤患者中发现了ETS因子ERG与雄激素调节的丝氨酸蛋白酶TMPRSS2的基因融合,其是癌症中最常见的基因重组之一。

TMPRSS2-ERG融合为雄激素诱导的ERG过表达和前列腺上皮细胞转录组的重编程提供了潜在的机制。然而,ERG异常表达影响肿瘤发生发展的相关机制尚不清楚。而了解潜在的发病机制可为该疾病提供新的预后和治疗工具。

该研究发现了促进ERG致癌活性的重要机制。研究人员发现,ERG的自抑制域内的一个特定赖氨酸残基(K362)能够被EZH2甲基化。机制研究显示,K362甲基化能够改变域内相互作用,有利于DNA的结合并增强ERG的转录活性。

EZH2甲基化ERG K362

在ERG融合阳性前列腺癌的转基因小鼠模型中,ERG K362甲基化与PTEN的缺失和疾病发展为侵袭性腺癌相关。在ERG阳性的VCaP细胞和ERG/PTEN小鼠中,PTEN的缺失能够诱导AKT的激活和EZH2 第21位丝氨酸残基的磷酸化,并有利于ERG的甲基化。

K362甲基化影响蛋白质的构象

进一步的研究发现,ERG能够与EZH2相互作用并共同占据基因组中的几个位点,以形成反式激活复合物。同样的,ERG/EZH2共调节的靶基因在ERG获得和PTEN缺失的肿瘤和去势抵抗性前列腺癌中能够优先的消除该调节作用。


总而言之,该研究结果确定ERG甲基化为一种翻译后修饰,其可维持ERG阳性前列腺癌的发生发展。


原始出处:

Zoma, M., Curti, L., Shinde, D. et al. EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer. Nat Commun 12, 4147 (06 July 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2022-05-31 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2022-02-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-10-09 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2022-04-06 kzlchina
  5. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-16 jambiya
  6. [GetPortalCommentsPageByObjectIdResponse(id=2088068, encodeId=a38520880685f, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue May 31 02:16:22 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885309, encodeId=e06c188530983, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 09 14:16:22 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746922, encodeId=79cf1e46922d9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Sat Oct 09 21:16:22 CST 2021, time=2021-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1669082, encodeId=aa8f1669082e8, content=<a href='/topic/show?id=bc2114e79b8' target=_blank style='color:#2F92EE;'>#PRS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14779, encryptionId=bc2114e79b8, topicName=PRS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=209526497271, createdName=kzlchina, createdTime=Wed Apr 06 14:16:22 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371037, encodeId=d9f813e1037fe, content=<a href='/topic/show?id=9c39864991e' target=_blank style='color:#2F92EE;'>#致癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86499, encryptionId=9c39864991e, topicName=致癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Fri Jul 16 13:16:22 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041045, encodeId=1764104104517, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jul 15 01:16:22 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:通过循环肿瘤DNA的低通量全基因组测序阐明前列腺癌治疗期间的特性

目前迫切需要更好的血液检测来阐明转移性去势抵抗性前列腺癌(mCRPC)的特性,以推动治疗决策。血浆无细胞DNA(cfDNA)包括正常和循环肿瘤DNA(ctDNA)。ctDNA的低通量全基因组测序(lp

JAMA Netw Open:化疗、恩杂鲁胺、阿比特龙和镭223与患有转移去势抵抗性前列腺癌老年男性认知功能的关系

老年人在接受各种肿瘤治疗时,认知能力下降的风险更大。一些常用的晚期前列腺癌治疗方法,如恩杂鲁胺,与认知障碍有关,但已公布的数据很少,这些数据来自单组研究或关注在自我报告的认知上。

Eur Urol:前列腺切除术后生化复发前列腺癌的强化剂量与常规剂量挽救性放疗比较

根治性前列腺切除术(RP)后的前列腺癌的生化进展一般采用挽救性放射治疗(SRT)。

BJU Int:根治性前列腺切除术中阳性手术边缘分类的临床应用

在根治性前列腺切除术(RP)样本中发现手术边缘阳性(PSM)意味着生化复发(BCR)的风险增加一倍。手术边缘状态包括两种,即阳性与阴性。在过去的十年中,人们越来越关注进一步的分类,包括PSM的数量、位

NEJM:磁共振成像可增加前列腺癌检出率并减少“过度诊断”

每年大约有 140 万男性被诊断出前列腺癌,375,000 人死于该疾病。先前有研究表明,早筛可以提早发现前列腺癌指证,从而降低前列腺癌死亡的风险。

J Urol:5-α还原酶抑制剂对MRI检测前列腺癌的影响

5-α还原酶抑制剂(5-ARIs)非那雄胺和度他雄胺是治疗继发于良性前列腺增生的下尿路症状的有效治疗方法,可降低急性尿潴留的风险,并减少前列腺增生男性对手术干预的需要。通过阻断5-&alp